April 7, 2015 11:36 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
(NASDAQ: BIND) shares were trading higher by $0.77 (15 percent) at $6.44 in Tuesday's session. The catalyst for the rally is the initiation of coverage by Oppenheimer with an Outperform rating along with a $14.00 price target.The clinical-stage nanomedicine platform company is developing targeted and programmable therapeutics called Accurins, recently announced an extension of a deal with Pfizer Inc to assist with the development of drugs in Pfizer's pipeline.That announcement failed to impressed investors as the issue only rallied from its April 2 ($5.52) to $5.67 on Monday.The Oppenheimer upgrade instigated a sharply higher opening (Monday's close of $5.67 vs. Tuesday's open of $6.35) with follow through to $6.65 before some profit-taking has taken the issue to its current level.The current intraday high coincides with a pair of highs in the issue from February 19 ($6.75) and February 20 ($6.69).
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.